Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Boothwyn Pharmacy, LLC

Has Boothwyn Pharmacy, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated January 16, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
January 16, 2026 (2026-01-16)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Compounding Pharmacy
Products named
Fluorescein 2% Ophthalmic SolutionTirzepatide 17mg/mL / Glycine 5mg/mL / Methylcobalamin 5mg/mL InjectionSemaglutide 2.5mg/mL InjectionTirzepatide 10mg/mL Injection
Violation categories
MisbrandingCGMP / insanitary conditionsFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says sterile drug products were made under insanitary conditions, including inadequate smoke studies and difficult-to-clean surfaces. Multiple lots were subpotent or failed sterility testing. Fluorescein, semaglutide, and tirzepatide labeling was false or misleading.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Adulterated drug products - insanitary conditions (501(a)(2)(A))
  • Adulterated - strength differs from official compendium standard (501(b))
  • Adulterated - strength/quality below represented (501(c))
  • Failed sterility testing
  • Misbranded - false or misleading labeling (502(a))
  • Deficient SOPs for at-risk release and OOS investigation/notification

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.